Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at HK$651 million, representing a 9.56% stake.

MP CARDIOFLOW announced the official release of one-year follow-up results from the early feasibility study for AltaValveTM, a transcatheter mitral valve replacement (TMVR) medical device independently developed by its associated company, 4C Medical Technologies, Inc. (4C Medical). This multicenter study spanned Europe, the United States, and Japan, enrolling 30 patients who were all at high surgical risk and had symptomatic severe mitral regurgitation (MR). Among the participants, 13 patients were treated using a transapical approach, while 17 received treatment via a transeptal approach.